Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis

por Merlini, G, Lousada, I, Ando, Y, Dispenzieri, A, Gertz, M A, Grogan, M, Maurer, M S, Sanchorawala, V, Wechalekar, A, Palladini, G, Comenzo, R L
Publicado 2016

P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

por Gertz, M., Cohen, A., Comenzo, R., Kastritis, E., Landau, H., Libby, E., Liedtke, M., Sanchorawala, V., Schönland, S., Wechalekar, A., Ando, Y., Koh, Y., Zonder, J., Palladini, G., Nie, C., Karp, C., Jin, Y., Conrad, A., Kinney, G., Merlini, G.
Publicado 2023